MET, also known as the hepatocyte growth factor receptor (HGFR), is a protein that is involved in cellular growth, survival, and migration. In some cancers, the MET gene may become altered or amplified, leading to increased MET signaling and contributing to tumor growth and progression.
Several targeted therapies have been developed or are under investigation for the treatment of MET-positive cancers. Some of these drugs include:
Capmatinib is a selective MET inhibitor approved for the treatment of metastatic NSCLC with a MET exon 14 skipping mutation. It has demonstrated efficacy in clinical trials for this specific patient population.
|Instructions for use:dosing, indications, interactions...etc.||https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213463s000lbl.pdf|
Savolitinib is another selective MET inhibitor currently under investigation for the treatment of various MET-positive cancers, including NSCLC, renal cell carcinoma, and gastric cancer.
|Instructions for use:dosing, indications, interactions...etc.||https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/212398s000lbl.pdf|
Tepotinib is a potent and selective MET inhibitor under investigation for the treatment of MET-positive tumors, including NSCLC and hepatocellular carcinoma.
|Instructions for use:dosing, indications, interactions...etc.||https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213372s000lbl.pdf|
These are just a few examples of the targeted drugs that have been developed or are under investigation for the treatment of MET-positive cancers. It's important to note that the effectiveness of these drugs will depend on the specific tumor type, the presence of other genetic alterations, and individual patient factors.Always consult with a healthcare professional to discuss the most appropriate treatment options for your specific situation.